Fujifilm Corp., of Tokyo, said its Alzheimer’s disease (AD) candidate, T-817MA, missed its primary endpoints of cognition or global clinical function in a U.S. phase II trial that enrolled individuals with mild to moderate AD. No significant differences were seen in secondary outcomes. In exploratory analyses, change of the cerebrospinal fluid biomarker phospho-tau, or p-Tau, benefited from higher dose treatment while hippocampal volumes decreased less in the lower dose group – a finding that met statistical significance.